Elbasvir

艾尔巴韦

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameElbasvir
Drug Alias NameElbasvirum依巴司韦ErelsaMK-8742
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNonstructural protein 5A inhibitors
TargetsNonstructural protein 5A
Therapy Area/IndicationsRenal InsufficiencyHepatic InsufficiencyHepatitis C, Chronic +[5] 
Global Approved IndicationsHepatitis C
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2016/09/28
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme Corp
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsHepatitis C
Inactive IndicationsRenal InsufficiencyHepatic InsufficiencyHepatitis C, Chronic +[4] 

Other Information

ATC CodeJ05AP10
Related LinksWikipediaDrugBankKEGG